Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
New Haven, Connecticut, United States
-
-
Florida
-
Tampa, Florida, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Minnesota
-
Rochester, Minnesota, United States
-
-
North Carolina
-
Huntersville, North Carolina, United States
-
-
Tennessee
-
Nashville, Tennessee, United States
-
-
Texas
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female, age 18 years or older.
- Willingness to provide written informed consent for the study.
- Part 1a: Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors that have failed prior standard therapy (including subject refusal or intolerance).
- Part 1b: Subjects with endometrial cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma, microsatellite unstable colorectal cancer, non-small cell lung cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, triple negative breast cancer, or transitional cell carcinoma of the genitourinary tract that have had disease progression after available therapies for metastatic disease that are known to confer clinical benefit, been intolerant to treatment, or refused standard treatment.
- Part 1b: Must have documented confirmed disease progression on a prior programmed cell death-1 (PD-1) pathway targeted agent or must be PD-1 pathway-targeted treatment naïve.
- Part 2: Subjects with HNSCC, NSCLC, pancreatic ductal adenocarcinoma, salivary gland cancer, and transitional cell carcinoma of the genitourinary tract that have had disease progression after available therapies for advanced or metastatic disease that are known to confer clinical benefit, have been intolerant to treatment, or have refused standard treatment.
- Willingness to undergo a pre-treatment and on-treatment tumor biopsy to obtain the specimen.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
- Laboratory parameters not within the protocol-defined range.
- Receipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.
- Received an immune-suppressive based treatment for any reason within 14 days prior to the first dose of study treatment.
- Has not recovered from toxic effect of prior therapy to < Grade 1.
- Active or inactive autoimmune process.
- Has received a live vaccine within 30 days of planned start of study therapy.
- Active infection requiring systemic therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Group A: Itacitinib + epacadostat
Group A will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
|
Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
Other Names:
Epacadostat tablets will be administered orally, twice daily.
|
|
Experimental: Group B: Itacitinib + INCB050465
Group B will utilize an open-label 3+3 dose-escalation design based on observing each dose level for a period of 21 days.
|
Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
Other Names:
INCB050465 tablets will be administered orally once daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Dose Limiting Toxicities (DLTs)
Time Frame: Baseline through 21 days
|
Safety and tolerability of the treatment groups.
|
Baseline through 21 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate (ORR)
Time Frame: Every 9 weeks for duration of study participation which is estimated to be 18 months
|
Tumor response rates in those subjects with measurable disease.
|
Every 9 weeks for duration of study participation which is estimated to be 18 months
|
|
Progression Free Survival (PFS)
Time Frame: Every 9 weeks for duration of study participation which is estimated to be 18 months
|
Progression-free survival, defined as the time from enrollment until the earliest date of disease progression.
|
Every 9 weeks for duration of study participation which is estimated to be 18 months
|
|
Duration of response (DOR)
Time Frame: Every 9 weeks for duration of study participation which is estimated to be 18 months
|
Duration of response determined by radiographic disease assessment.
|
Every 9 weeks for duration of study participation which is estimated to be 18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 39110-106
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.